A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801
This study is recruiting at 10 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Los Angeles Cancer Network - Anaheim · Anaheim, CA
- Stanford Cancer Institute · Palo Alto, CA
Florida · 1
- Cancer Specialists of North Florida · Jacksonville, FL
Minnesota · 1
- Avera Cancer Institute - Marshall · Marshall, MN
South Dakota · 5
- Avera Cancer Institute - Aberdeen · Aberdeen, SD
- Avera Cancer Institute - Mitchell · Mitchell, SD
- Avera Cancer Institute - Pierre, SD · Pierre, SD
- Avera Cancer Institute · Sioux Falls, SD
- AMG Oncology and Hematology Avera Cancer Institute - Yankton · Yankton, SD
Wisconsin · 1
- Medical College of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.